
Sintilimab plus fruquintinib under review in China for advanced renal cell carcinoma
China’s National Medical Products Administration (NMPA) has accepted a new drug application (NDA) seeking approval of sintilimab (Tyvyt) plus fruquintinib (Elunate) for patients with locally advanced or metastatic renal cell carcinoma (RCC) who have failed …